% | $
Quotes you view appear here for quick access.

Ariad Pharmaceuticals Inc. Message Board

  • rob_cos rob_cos Feb 7, 2013 6:59 PM Flag

    BMO"Buy weakness. $36 target. CML=$250 mill/yr sales. Launch review sees $3 mill Q1 vs $1 mill est" BUY

    BMO on ARIA "CML recurring incremental $250 mill/yr sales? Launch review suggests $3 mill Q1 sales vs $1 mill ests. Investors should buy weakness ahead of multiple catlysts. $36 target"

    Stock closed today $19.80

    Thursday, February 7, 2013

    BMO Capital Markets

    Ariad Pharmaceuticals (Outperform)

    TARGET $36.00

    Addressing Weakness in ARIA Shares, Launch on Track

    Flash: We have a significant amount of inbound inquiry regarding weakness in ARIA shares and what might be driving it today. We've had opportunity to speak with ARIA directly, and the company isn't aware of an event or an impending event that would explain the weakness. In particular, there is no update on launch progress for ICLUSIG, regulatory progress in Europe, or data update on AP26113. At present, the primary focus of investor interest remains on the ICLUSIG launch with four full weeks of prescription data reported by IMS Health. While we are precluded from sharing specific detail of IMS prescription data, we would note that the cumulative total over four weeks is identical to the first month of Tasigna TRx's, and we believe that the capture rate is

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.73+0.17(+2.53%)May 5 4:00 PMEDT